The company Entest Biomedical (ENTB) continues to hone in on their goals while securing potential funding opportunities on the way. This is possibly one of the most alluring positions of this stock. Not only is ENTB endlessly trying to find a solid treatment/cure for COPD but also making headway in other areas that stand to increase the value of the company exponentially.

The CEO and Chairman of ENTB states: "Since some of these technologies may be useful in augmentation of stem cell therapy for other indications, we are always looking for partnerships for development in our non-core areas." This shows that they are continuing to focus in on their ultimate goal of an FDA-approved treatment for COPD but leaving the door open to pursue partnerships and other sources of funds along the way. To investors, this stock is panning out to be a perfect match of research with real progress.

The patent Entest Biomedical, Inc. is filing for is for the use of stem cell attracting chemokines in treating COPD in addition to other medical conditions that can benefit from stem cell homing. Essentially, it is increasing the number of stem cells in the tissues where they are needed throughout the body to increase repair.

Stem cell trials show that they are safe and increase desired results in liver and heart failure as well as peripheral artery disease; however, more tests need to be conducted to improve the actual patient’s outcomes.

What ENTB is doing is completely different than current cell homing which involves making stem cells leave areas such as bone marrow. ENTB is using chemokines, the attracting molecule, to bring in the stem cells. Overall, the process is very safe and could potentially produce a much more effective outcome.

We have said it before and our opinions have not changed; ENTB is on a mission to bring the best out of medicine and explore areas that have not been explored or revisit past methods and make them more efficient or better yet, a solution to a problem.

This new patent application is just one of the many announcements we expect to hear from Entest Biomedical, Inc. Their mission is clear, they uphold stockholder value and they look beyond what is in front of them and into the future. This is the type of company that we want paving the ways to new discoveries in medicine and we will be there every step of the way.

Today, the CEO Dr. David Koos and ENTB’s Lead Inventor discussed the recent patent more in-depth. You will not want to miss the video and can view it online right now here: http://www.entestbioblog.com/entb-live-webcast-on-march-24-2010/